The role of lipid biomarkers in major depression

Healthcare (Switzerland)

Volumn 5, Issue 1, 2017, Pages

  Parekh, Amy ^a   Smeeth, Demelza ^a   Milner, Yasmin ^a   Thuret, Sandrine ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cholesterol; Lipid biomarkers; Major depressive disorder; Polyunsaturated fatty acids

Indexed keywords

EID: 85021774402     PISSN: None     EISSN: 22279032     Source Type: Journal    
DOI: 10.3390/healthcare5010005     Document Type: Review

References (154)

1. Bogavac-Stanojevic, N.; Lakic, D. Biomarkers for major depressive disorder: Economic considerations. Drug Dev. Res. 2016, 77, 374–378. [CrossRef] [PubMed]
2. Fava, M.; Kendler, K.S. Major depressive disorder. Neuron 2000, 28, 335–341. [CrossRef]
3. Smith, D.J.; Nicholl, B.I.; Cullen, B.; Martin, D.; Ul-Haq, Z.; Evans, J.; Gill, J.M.; Roberts, B.; Gallacher, J.; Mackay, D.; et al. Prevalence and characteristics of probable major depression and bipolar disorder within uk biobank: Cross-sectional study of 172,751 participants. PLoS ONE 2013, 8, e75362. [CrossRef] [PubMed]
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Dsm-5®); American Psychiatric Pub: Arlington, VA, USA, 2013.
5. Woo, J.-M.; Kim, W.; Hwang, T.-Y.; Frick, K.D.; Choi, B.H.; Seo, Y.-J.; Kang, E.-H.; Kim, S.J.; Ham, B.-J.; Lee, J.-S.; et al. Impact of depression on work productivity and its improvement after outpatient treatment with antidepressants. Value Health 2011, 14, 475–482. [CrossRef] [PubMed]
6. Mueller, T.I.; Leon, A.C. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr. Clin. N. Am. 1996, 19, 85–102. [CrossRef]
7. Posternak, M.A.; Solomon, D.A.; Leon, A.C.; Mueller, T.I.; Shea, M.T.; Endicott, J.; Keller, M.B. The naturalistic course of unipolar major depression in the absence of somatic therapy. J. Nerv. Ment. Dis. 2006, 194, 324–329. [CrossRef] [PubMed]
8. Blair-West, G.W.; Cantor, C.H.; Mellsop, G.W.; Eyeson-Annan, M.L. Lifetime suicide risk in major depression: Sex and age determinants. J. Affect. Disord. 1999, 55, 171–178. [CrossRef]
9. Alboni, P.; Favaron, E.; Paparella, N.; Sciammarella, M.; Pedaci, M. Is there an association between depression and cardiovascular mortality or sudden death? J. Cardiovasc. Med. 2008, 9, 356–362. [CrossRef] [PubMed]
10. Mitchell, A.J.; Vaze, A.; Rao, S. Clinical diagnosis of depression in primary care: A meta-analysis. Lancet 2009, 374, 609–619. [CrossRef]
11. De Sousa, R.T.; V Zanetti, M.; R Brunoni, A.; Machado-Vieira, R. Challenging treatment–resistant major depressive disorder: A roadmap for improved therapeutics. Curr. Neuropharmacol. 2015, 13, 616–635. [CrossRef] [PubMed]
12. Kirsch, I. Antidepressants and the placebo effect. Z. Psychol. 2014, 222, 128–134. [CrossRef] [PubMed]
13. Domenici, E.; Willé, D.R.; Tozzi, F.; Prokopenko, I.; Miller, S.; McKeown, A.; Brittain, C.; Rujescu, D.; Giegling, I.; Turck, C.W.; et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 2010, 5, e9166. [CrossRef] [PubMed]
14. Gross, R.W.; Jenkins, C.M.; Yang, J.; Mancuso, D.J.; Han, X. Functional lipidomics: The roles of specialized lipids and lipid-protein interactions in modulating neuronal function. Prostag. Oth. Lipid. Mediat. 2005, 77, 52–64. [CrossRef] [PubMed]
15. Tsui-Pierchala, B.A.; Encinas, M.; Milbrandt, J.; Johnson, E.M. Lipid rafts in neuronal signaling and function. Trends Neurosci. 2002, 25, 412–417. [CrossRef]
16. Partonen, T.; Haukka, J.; Virtamo, J.; Taylor, P. Association of low serum total cholesterol with major depression and suicide. Br. J. Psychiatry 1999, 175, 259–262. [CrossRef]
17. Björkhem, I.; Meaney, S. Brain cholesterol: Long secret life behind a barrier. Arterioscler. Thromb. 2004, 24, 806–815. [CrossRef] [PubMed]
18. Saher, G.; Brügger, B.; Lappe-Siefke, C.; Möbius, W.; Tozawa, R.-I.; Wehr, M.C.; Wieland, F.; Ishibashi, S.; Nave, K.-A. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 2005, 8, 468–475. [CrossRef] [PubMed]
19. Dietschy, J.M.; Turley, S.D. Thematic review series: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45, 1375–1397. [CrossRef] [PubMed]
20. Zhang, J.; Liu, Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 2015, 6, 254–264. [CrossRef] [PubMed]
21. Gupta, A.; Jadhav, A.; Petkar, S.; Dubey, V. Study of lipid derangement in pyschiatric disorder. Indian Med. Gaz. 2013, 253–256.
22. Alphonse, P.A.; Jones, P.J. Revisiting human cholesterol synthesis and absorption: The reciprocity paradigm and its key regulators. Lipids 2016, 51, 519–536. [CrossRef] [PubMed]
23. Müller, C.P.; Reichel, M.; Muehle, C.; Rhein, C.; Gulbins, E.; Kornhuber, J. Brain membrane lipids in major depression and anxiety disorders. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2015, 1851, 1052–1065. [CrossRef] [PubMed]
24. Lütjohann, D.; Stroick, M.; Bertsch, T.; Kühl, S.; Lindenthal, B.; Thelen, K.; Andersson, U.; Björkhem, I.; Von Bergmann, K.; Fassbender, K. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004, 69, 431–438. [CrossRef] [PubMed]
25. Ariyo, A.A.; Haan, M.; Tangen, C.M.; Rutledge, J.C.; Cushman, M.; Dobs, A.; Furberg, C.D.; Group, C.H.S.C.R. Depressive symptoms and risks of coronary heart disease and mortality in elderly americans. Circulation 2000, 102, 1773–1779. [CrossRef] [PubMed]
26. Penninx, B.W.; Beekman, A.T.; Honig, A.; Deeg, D.J.; Schoevers, R.A.; Van Eijk, J.T.; Van Tilburg, W. Depression and cardiac mortality: Results from a community-based longitudinal study. Arch. Gen. Psychiatry 2001, 58, 221–227. [CrossRef] [PubMed]
27. Jiang, W.; Alexander, J.; Christopher, E.; Kuchibhatla, M.; Gaulden, L.H.; Cuffe, M.S.; Blazing, M.A.; Davenport, C.; Califf, R.M.; Krishnan, R.R.; et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch. Intern. Med. 2001, 161, 1849–1856. [CrossRef] [PubMed]
28. Martens, E.J.; Hoen, P.W.; Mittelhaeuser, M.; De Jonge, P.; Denollet, J. Symptom dimensions of post-myocardial infarction depression, disease severity and cardiac prognosis. Psychol. Med. 2010, 40, 807–814. [CrossRef] [PubMed]
29. Travella, J.I.; Forrester, A.W.; Schultz, S.K.; Robinson, R.G. Depression following myocardial infarction: A one year longitudinal study. Int. J. Psychiatry Med. 1994, 24, 357–369. [CrossRef] [PubMed]
30. Steeds, R.P.; Bickerton, D.; Smith, M.J.; Muthusamy, R. Assessment of depression following acute myocardial infarction using the beck depression inventory. Heart 2004, 90, 217–218. [CrossRef] [PubMed]
31. Trpkovic, A.; Resanovic, I.; Stanimirovic, J.; Radak, D.; Mousa, S.A.; Cenic-Milosevic, D.; Jevremovic, D.; Isenovic, E.R. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit. Rev. Clin. Lab. Sci. 2015, 52, 70–85. [CrossRef] [PubMed]
32. Barter, P. The role of hdl-cholesterol in preventing atherosclerotic disease. Eur. Heart J. Suppl. 2005, 7, F4–F8. [CrossRef]
33. Terao, T.; Iwata, N.; Kanazawa, K.; Takano, T.; Takahashi, N.; Hayashi, T.; Sugawara, Y. Low serum cholesterol levels and depressive state in human dock visitors. Acta Psychiatr. Scand. 2000, 101, 231–234. [CrossRef] [PubMed]
34. Horsten, M.; Wamala, S.P.; Vingerhoets, A.; Orth-Gomer, K. Depressive symptoms, social support, and lipid profile in healthy middle-aged women. Psychosom. Med. 1997, 59, 521–528. [CrossRef] [PubMed]
35. Rabe-Jabłońska, J.; Poprawska, I. Levels of serum total cholesterol and ldl-cholesterol in patients with major depression in acute period and remission. Med. Sci. Monit. 2000, 6, 539–547. [PubMed]
36. Olusi, S.O.; Fido, A.A. Serum lipid concentrations in patients with major depressive disorder. Biol. Psychiatry 1996, 40, 1128–1131. [CrossRef]
37. Lehto, S.M.; Niskanen, L.; Tolmunen, T.; Hintikka, J.; Viinamaki, H.; Heiskanen, T.; Honkalampi, K.; Kokkonen, M.; Koivumaa-Honkanen, H. Low serum hdl-cholesterol levels are associated with long symptom duration in patients with major depressive disorder. Psychiatry Clin. Neurosci. 2010, 64, 279–283. [CrossRef] [PubMed]
38. De Freitas, J.A.; Lima, L.M.; Ranieri, J.L.; Olivieri, J.C.; Fragoso, H.J.; Chinzon, D. Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases. Arq. Gastroenterol. 2002, 39, 60–65. [PubMed]
39. Sadeghi, M.; Roohafza, H.; Afshar, H.; Rajabi, F.; Ramzani, M.; Shemirani, H.; Sarafzadeghan, N. Relationship between depression and apolipoproteins a and b: A case-control study. Clinics 2011, 66, 113–117. [CrossRef] [PubMed]
40. Brown, S.L.; Salive, M.E.; Harris, T.B.; Simonsick, E.M.; Guarlnik, J.; Kohout, F.J. Low cholesterol concentrations and severe depressive symptoms in elderly people. BMJ 1994, 308, 1328–1332. [CrossRef] [PubMed]
41. Ergun, U.G.; Uguz, S.; Bozdemir, N.; Guzel, R.; Burgut, R.; Saatci, E.; Akpinar, E. The relationship between cholesterol levels and depression in the elderly. Int. J. Geriatr. Psychiatry 2004, 19, 291–296. [CrossRef] [PubMed]
42. Huang, T.-L. Serum lipid profiles in major depression with clinical subtypes, suicide attempts and episodes. J. Affect. Disord. 2005, 86, 75–79. [CrossRef] [PubMed]
43. Shin, J.Y.; Suls, J.; Martin, R. Are cholesterol and depression inversely related? A meta-analysis of the association between two cardiac risk factors. Ann. Behav. Med. 2008, 36, 33–43. [CrossRef] [PubMed]
44. Persons, J.E.; Fiedorowicz, J.G. Depression and serum low-density lipoprotein: A systematic review and meta-analysis. J. Affect. Disord. 2016, 206, 55–67. [CrossRef] [PubMed]
45. Guardiola, M.; Sola, R.; Vallve, J.C.; Girona, J.; Godas, G.; Heras, M.; Gonzalez, M.; Rock, E.; Winklhoffer-Roob, B.M.; Masana, L.; et al. Body mass index correlates with atherogenic lipoprotein profile even in nonobese, normoglycemic, and normolipidemic healthy men. J. Clin. Lipidol. 2015, 9, 824–831. [CrossRef] [PubMed]
46. Simon, G.E.; Von Korff, M.; Saunders, K.; Miglioretti, D.L.; Crane, P.K.; Van Belle, G.; Kessler, R.C. Association between obesity and psychiatric disorders in the us adult population. Arch. Gen. Psychiatry 2006, 63, 824–830. [CrossRef] [PubMed]
47. Bjerkeset, O.; Romundstad, P.; Evans, J.; Gunnell, D. Association of adult body mass index and height with anxiety, depression, and suicide in the general population. Am. J. Epidemiol. 2008, 167, 193–202. [CrossRef] [PubMed]
48. Ho, R.C.M.; Niti, M.; Kua, E.H.; Ng, T.P. Body mass index, waist circumference, waits-hip ratio and depressive symptoms in chinese elderly: A population-based study. Int. J. Geriatr. Psychiatry 2008, 23, 401–408. [CrossRef] [PubMed]
49. Colin, A.; Reggers, J.; Castronovo, V.; Ansseau, M. Lipids, depression and suicide. Encephale 2002, 29, 49–58.
50. Boston, P.F.; Dursun, S.M.; Reveley, M.A. Cholesterol and mental disorder. Br. J. Psychiatry 1996, 169, 682–689. [CrossRef] [PubMed]
51. Maes, M.; Smith, R.; Christophe, A.; Vandoolaeghe, E.; Gastel, A.V.; Neels, H.; Demedts, P.; Wauters, A.; Meltzer, H. Lower serum high-density lipoprotein cholesterol (hdl-c) in major depression and in depressed men with serious suicidal attempts: Relationship with immune-inflammatory markers. Acta Psychiatr. Scand. 1997, 95, 212–221. [CrossRef] [PubMed]
52. Sarchiapone, M.; Camardese, G.; Roy, A.; Della Casa, S.; Satta, M.A.; Gonzalez, B.; Berman, J.; De Risio, S. Cholesterol and serotonin indices in depressed and suicidal patients. J. Affect. Disord. 2001, 62, 217–219. [CrossRef]
53. Atmaca, M.; Kuloglu, M.; Tezcan, E.; Ustundag, B.; Gecici, O.; Firidin, B. Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology 2002, 45, 124–127. [CrossRef] [PubMed]
54. Kunugi, H.; Takei, N.; Aoki, H.; Nanko, S. Low serum cholesterol in suicide attempters. Biol. Psychiatry 1997, 41, 196–200. [CrossRef]
55. Zureik, M.; Courbon, D.; Ducimetiere, P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996, 313, 649–651. [CrossRef] [PubMed]
56. Kim, Y.K.; Lee, H.J.; Kim, J.Y.; Yoon, D.K.; Choi, S.H.; Lee, M.S. Low serum cholesterol is correlated to suicidality in a korean sample. Acta Psychiatr. Scand. 2002, 105, 141–148. [CrossRef] [PubMed]
57. Ellison, L.F.; Morrison, H.I. Low serum cholesterol concentration and risk of suicide. Epidemiology 2001, 12, 168–172. [CrossRef] [PubMed]
58. Bocchetta, A.; Chillotti, C.; Carboni, G.; Oi, A.; Ponti, M.; Del Zompo, M. Association of personal and familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta Psychiatr. Scand. 2001, 104, 37–41. [CrossRef] [PubMed]
59. Modai, I.; Valevski, A.; Dror, S.; Weizman, A. Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. J. Clin. Psychiatry 1994, 55, 252–254. [PubMed]
60. Papassotiropoulos, A.; Hawellek, B.; Frahnert, C.; Rao, G.; Rao, M.L. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol. Pharmacopsychiatry 1999, 32, 1–4. [CrossRef] [PubMed]
61. Sullivan, P.F.; Joyce, P.R.; Bulik, C.M.; Mulder, R.T.; Oakley-Browne, M. Total cholesterol and suicidality in depression. Biol. Psychiatry 1994, 36, 472–477. [CrossRef]
62. Hawthon, K.; Cowen, P.; Owens, D.; Bond, A.; Elliott, M. Low serum cholesterol and suicide. Br. J. Psychiatry 1993, 162, 818–825. [CrossRef] [PubMed]
63. Engelberg, H. Low serum cholesterol and suicide. Lancet 1992, 339, 727–729. [CrossRef]
64. Ahmadpanah, M.; Haghighi, M.; Jahangard, L.; Borzoei, S.; Heshmati, S.; Bajoghli, H.; Holsboer-Trachsler, E.; Brand, S. No evidence for metabolic syndrome and lipid profile differences in patients suffering from bipolar i disorder with and without suicide attempts. Int. J. Psychiatry Clin. 2015, 19, 168–173. [CrossRef] [PubMed]
65. Roohafza, H.; Sadeghi, M.; Afshar, H.; Mousavi, G.; Shirani, S. Evaluation of lipid profile in patient with major depressive disorder and generalized anxiety disorder. ARYA Atheroscler. 2010, 1, 1518.
66. Peter, H.; Hand, I.; Hohagen, F.; Koenig, A.; Mindermann, O.; Oeder, F.; Wittich, M. Serum cholesterol level comparison: Control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Can. J. Psychiatry 2002, 47, 557–561. [PubMed]
67. Sevincok, L.; Buyukozturk, A.; Dereboy, F. Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder. Can. J. Psychiatry 2001, 46, 68–71. [PubMed]
68. Kagan, B.L.; Leskin, G.; Haas, B.; Wilkins, J.; Foy, D. Elevated lipid levels in vietnam veterans with chronic posttraumatic stress disorder. Biol. Psychiatry 1999, 45, 374–377. [CrossRef]
69. Bajwa, W.K.; Asnis, G.M.; Sanderson, W.C.; Irfan, A.; Van Praag, H.M. High cholesterol levels in patients with panic disorder. Am. J. Psychiatry 1992, 149, 376–378. [PubMed]
70. Agargun, M.Y.; Dulger, H.; Inci, R.; Kara, H.; Ozer, O.A.; Sekeroglu, M.R.; Besiroglu, L. Serum lipid concentrations in obsessive-compulsive disorder patients with and without panic attacks. Can. J. Psychiatry 2004, 49, 776–778.
71. Agargun, M.Y.; Algun, E.; Sekeroglu, R.; Kara, H.; Tarakcioglu, M. Low cholesterol level in patients with panic disorder: The association with major depression. J. Affect. Disord. 1998, 50, 29–32. [CrossRef]
72. Scanlon, S.M.; Williams, D.C.; Schloss, P. Membrane cholesterol modulates serotonin transporter activity. Biochemistry 2001, 40, 10507–10513. [CrossRef] [PubMed]
73. Heron, D.S.; Shinitzky, M.; Hershkowitz, M.; Samuel, D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc. Natl. Acad. Sci. USA 1980, 77, 7463–7467. [CrossRef] [PubMed]
74. Sun, S.; Yang, S.; Mao, Y.; Jia, X.; Zhang, Z. Reduced cholesterol is associated with the depressive-like behavior in rats through modulation of the brain 5-HT1A receptor. Lipids Health Dis. 2015, 14, 22–32. [CrossRef] [PubMed]
75. Maes, M. The cytokine hypothesis of depression: Inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett. 2008, 29, 287–291. [PubMed]
76. Stewart, J.C.; Rand, K.L.; Muldoon, M.F.; Kamarck, T.W. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav. Immun. 2009, 23, 936–944. [CrossRef] [PubMed]
77. Kurano, M.; Iso-O, N.; Hara, M.; Noiri, E.; Koike, K.; Kadowaki, T.; Tsukamoto, K. Plant sterols increased il-6 and tnf-alpha secretion from macrophages, but to a lesser extent than cholesterol. J. Atheroscler. Thromb. 2011, 18, 373–383. [CrossRef] [PubMed]
78. Torres, R.J.D.; Luchini, A.; Barberini, L.Y.; Precoma, L.; Torres, C.L.D.; Torres, R.A.D.; De Noronha, L.; Erbano, B.O.; Casella, A.M.B.; Precoma, D.B. Expression of tnf-alpha and il-6 cytokines in the choroid and sclera of hypercholesterolemic rabbits. Arq. Bras. Oftalmol. 2014, 77, 168–172. [CrossRef] [PubMed]
79. Ma, K.; Zhang, H.X.; Baloch, Z. Pathogenetic and therapeutic applications of tumor necrosis factor-alpha (tnf-alpha) in major depressive disorder: A systematic review. Int. J. Mol. Sci. 2016, 17, 733–753. [CrossRef] [PubMed]
80. Liu, Y.; Ho, R.C.M.; Mak, A. Interleukin (il)-6, tumour necrosis factor alpha (tnf-alpha) and soluble interleukin-2 receptors (sil-2r) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J. Affect. Disord. 2012, 139, 230–239. [CrossRef] [PubMed]
81. Lin, S.J.; Yen, H.T.; Chen, Y.H.; Ku, H.H.; Lin, F.Y.; Chen, Y.L. Expression of interleukin-1 beta and interleukin-1 receptor antagonist in oxldl-treated human aortic smooth muscle cells and in the neointima of cholesterol-fed endothelia-denuded rabbits. J. Cell. Biochem. 2003, 88, 836–847. [CrossRef] [PubMed]
82. Ovaskainen, Y.; Koponen, H.; Jokelainen, J.; Keinaenen-Kiukaannniemi, S.; Kumpusalo, E.; Vanhala, M. Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res. 2009, 167, 73–79. [CrossRef] [PubMed]
83. Gabriel, A. Changes in plasma cholesterol in mood disorder patients: Does treatment make a difference? J. Affect. Disord. 2007, 99, 273–278. [CrossRef] [PubMed]
84. Whitney, E.J.; Krasuski, R.A.; Personius, B.E.; Michalek, J.E.; Maranian, A.M.; Kolasa, M.W.; Monick, E.; Brown, B.G.; Gotto, A.M. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann. Intern. Med. 2005, 142, 95–104. [CrossRef] [PubMed]
85. Ghanizadeh, A.; Hedayati, A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress. Anxiety 2013, 30, 1084–1088. [CrossRef] [PubMed]
86. Haghighi, M.; Khodakarami, S.; Jahangard, L.; Ahmadpanah, M.; Bajoghli, H.; Holsboer-Trachsler, E.; Brand, S. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. J. Psychiatr. Res. 2014, 58, 109–114. [CrossRef] [PubMed]
87. Parsaik, A.K.; Singh, B.; Murad, M.H.; Singh, K.; Mascarenhas, S.S.; Williams, M.D.; Lapid, M.I.; Richardson, J.W.; West, C.P.; Rummans, T.A. Statins use and risk of depression: A systematic review and meta-analysis. J. Affect. Disord. 2014, 160, 62–67. [CrossRef] [PubMed]
88. Salehi, I.; Hosseini, S.M.; Haghighi, M.; Jahangard, L.; Bajoghli, H.; Gerber, M.; Puhse, U.; Holsboer-Trachsler, E.; Brand, S. Electroconvulsive therapy (ect) and aerobic exercise training (aet) increased plasma bdnf and ameliorated depressive symptoms in patients suffering from major depressive disorder. J. Psychiatr. Res. 2016, 76, 1–8. [CrossRef] [PubMed]
89. Kurt, E.; Guler, O.; Serteser, M.; Cansel, N.; Ozbulut, O.; Altınbaş, K.; Alataş, G.; Savaş, H.; Gecici, O. The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders. Neurosci. Lett. 2007, 426, 49–53. [CrossRef] [PubMed]
90. Schmitz, G.; Ecker, J. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 2008, 47, 147–155. [CrossRef] [PubMed]
91. Greenwood, C.E.; Young, S.N. Dietary fat intake and the brain: A developing frontier in biological psychiatry. J. Psychiatr. Neurosci. 2001, 26, 182.
92. Martinez, M. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 1992, 120, S129–S138. [CrossRef]
93. Simopoulos, A.P. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr. 1991, 54, 438–463. [PubMed]
94. Bourre, J. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. 2004, 8, 163–174.
95. Maes, M.; Smith, R.; Christophe, A.; Cosyns, P.; Desnyder, R.; Meltzer, H. Fatty acid composition in major depression: Decreased ω3 fractions in cholesteryl esters and increased c20: 4ω6c20: 5ω3 ratio in cholesteryl esters and phospholipids. J. Affect. Disord. 1996, 38, 35–46. [CrossRef]
96. Hibbeln, J.R.; Salem, N. Dietary polyunsaturated fatty acids and depression: When cholesterol does not satisfy. Am. J. Clin. Nutr. 1995, 62, 1–9. [PubMed]
97. Maes, M.; Christophe, A.; Delanghe, J.; Altamura, C.; Neels, H.; Meltzer, H.Y. Lowered ω3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999, 85, 275–291. [CrossRef]
98. Peet, M.; Murphy, B.; Shay, J.; Horrobin, D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry 1998, 43, 315–319. [CrossRef]
99. Edwards, R.; Peet, M.; Shay, J.; Horrobin, D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect. Disord. 1998, 48, 149–155. [CrossRef]
100. Hibbeln, J.R. Fish consumption and major depression. Lancet 1998, 351, 1213. [CrossRef]
101. Simopoulos, A.P. The Return of W3 Fatty Acids into the Food Supply: Land-Based Animal Food Products and Their Health Effects; Karger Medical and Scientific Publishers: Washington, DC, USA, 1998.
102. Yoshikawa, E.; Nishi, D.; Matsuoka, Y. Fish consumption and resilience to depression in Japanese company workers: A cross-sectional study. Lipids Health Dis. 2015, 14, 51–58. [CrossRef] [PubMed]
103. Sanchez-Villegas, A.; Henriquez, P.; Figueiras, A.; Ortuno, F.; Lahortiga, F.; Martinez-Gonzalez, M.A. Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the sun cohort study. Eur. J. Nutr. 2007, 46, 337–346. [CrossRef] [PubMed]
104. Del Brutto, O.H.; Mera, R.M.; Gillman, J.; Zambrano, M.; Ha, J.E. Oily fish intake and cognitive performance in community-dwelling older adults: The atahualpa project. J. Commun. Health 2016, 41, 82–86. [CrossRef] [PubMed]
105. Bountziouka, V.; Polychronopoulos, E.; Zeimbekis, A.; Papavenetiou, E.; Ladoukaki, E.; Papairakleous, N.; Gotsis, E.; Metallinos, G.; Lionis, C.; Panagiotakos, D. Long-term fish intake is associated with less severe depressive symptoms among elderly men and women: The medis (Mediterranean Islands elderly) epidemiological study. J. Aging Health 2009, 21, 864–880. [CrossRef] [PubMed]
106. Smith, K.J.; Sanderson, K.; McNaughton, S.A.; Gall, S.L.; Dwyer, T.; Venn, A.J. Longitudinal associations between fish consumption and depression in young adults. Am. J. Epidemiol. 2014, 179, 1228–1235. [CrossRef] [PubMed]
107. Li, Y.; Dai, Q.; Ekperi, L.I.; Dehal, A.; Zhang, J. Fish consumption and severely depressed mood, findings from the first national nutrition follow-up study. Psychiatry Res. 2011, 190, 103–109. [CrossRef] [PubMed]
108. Van West, D.; Maes, M. Polyunsaturated fatty acids in depression. Acta Neuropsychiatr. 2003, 15, 15–21. [CrossRef] [PubMed]
109. Rao, T.S.; Asha, M.; Ramesh, B.; Rao, K.J. Understanding nutrition, depression and mental illnesses. Indian J. Psychiatry 2008, 50, 77–82.
110. Adams, P.B.; Lawson, S.; Sanigorski, A.; Sinclair, A.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996, 31, S157–S161. [CrossRef] [PubMed]
111. Hibbeln, J.R. Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets. World Rev. Nutr. Diet. 2009, 99, 17–30. [PubMed]
112. Tiemeier, H.; Van Tuijl, H.R.; Hofman, A.; Kiliaan, A.J.; Breteler, M.M. Plasma fatty acid composition and depression are associated in the elderly: The rotterdam study. Am. J. Clin. Nutr. 2003, 78, 40–46.
113. Riemer, S.; Maes, M.; Christophe, A.; Rief, W. Lowered omega-3 pufas are related to major depression, but not to somatization syndrome. J. Affect. Disord. 2010, 123, 173–180. [CrossRef] [PubMed]
114. Frasure-Smith, N.; Lesperance, F.; Julien, P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol. Psychiatry 2004, 55, 891–896. [CrossRef] [PubMed]
115. Beydoun, M.A.; Fanelli Kuczmarski, M.T.; Beydoun, H.A.; Rostant, O.S.; Evans, M.K.; Zonderman, A.B. Associations of the ratios of n-3 to n-6 dietary fatty acids with longitudinal changes in depressive symptoms among us women. Am. J. Epidemiol. 2015, 181, 691–705. [CrossRef] [PubMed]
116. Fehily, A.M.; Bowey, O.A.; Ellis, F.R.; Meade, B.W.; Dickerson, J.W. Plasma and erythrocyte membrane long chain polyunsaturated fatty acids in endogenous depression. Neurochem. Int. 1981, 3, 37–42. [CrossRef]
117. Aupperle, R.L.; Denney, D.R.; Lynch, S.G.; Carlson, S.E.; Sullivan, D.K. Omega-3 fatty acids and multiple sclerosis: Relationship to depression. J. Behav. Med. 2008, 31, 127–135. [CrossRef] [PubMed]
118. Lin, P.Y.; Huang, S.Y.; Su, K.P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 2010, 68, 140–147. [CrossRef] [PubMed]
119. Hirashima, F.; Parow, A.M.; Stoll, A.L.; Demopulos, C.M.; Damico, K.E.; Rohan, M.L.; Eskesen, J.G.; Zuo, C.S.; Cohen, B.M.; Renshaw, P.F. Omega-3 fatty acid treatment and t2 whole brain relaxation times in bipolar disorder. Am. J. Psychiatry 2004, 161, 1922–1924. [CrossRef] [PubMed]
120. Zheng, P.; Gao, H.C.; Li, Q.; Shao, W.H.; Zhang, M.L.; Cheng, K.; Yang, D.Y.; Fan, S.H.; Chen, L.; Fang, L. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Proteome Res. 2012, 11, 1741–1748. [CrossRef] [PubMed]
121. Sidhu, V.K.; Huang, B.X.; Kim, H.–Y. Effects of docosahexaenoic acid on mouse brain synaptic plasma membrane proteome analyzed by mass spectrometry and 16o/18o labeling. J. Proteome Res. 2011, 10, 5472–5480. [CrossRef] [PubMed]
122. Cao, D.; Kevala, K.; Kim, J.; Moon, H.S.; Jun, S.B.; Lovinger, D.; Kim, H.Y. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J. Neurochem. 2009, 111, 510–521. [CrossRef] [PubMed]
123. Kim, H.-Y.; Moon, H.-S.; Cao, D.; Lee, J.; Kevala, K.; Jun, S.B.; Lovinger, D.M.; Akbar, M.; Huang, B.X. N-docosahexaenoylethanolamide promotes development of hippocampal neurons. Biochem. J. 2011, 435, 327–336. [CrossRef] [PubMed]
124. Mayurasakorn, K.; Niatsetskaya, Z.V.; Sosunov, S.A.; Williams, J.J.; Zirpoli, H.; Vlasakov, I.; Deckelbaum, R.J.; Ten, V.S. Dha but not epa emulsions preserve neurological and mitochondrial function after brain hypoxia-ischemia in neonatal mice. PLoS ONE 2016, 11, e0160870. [CrossRef] [PubMed]
125. Almeida-Montes, L.G.; Valles-Sanchez, V.; Moreno-Aguilar, J.; Chavez-Balderas, R.A.; García-Marín, J.A.; Sotres, J.C.; Hheinze-Martin, G. Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts. J. Psychiatry Neurosci. 2000, 25, 371–377.
126. DiPatrizio, N.V.; Piomelli, D. The thrifty lipids: Endocannabinoids and the neural control of energy conservation. Trends Neurosci. 2012, 35, 403–411. [CrossRef] [PubMed]
127. Patterson, E.; Wall, R.; Fitzgerald, G.F.; Ross, R.P.; Stanton, C. Health implications of high dietary omega-6 polyunsaturated fatty acids. J. Nutr. Metab. 2012, 2012. [CrossRef] [PubMed]
128. Calder, P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br. J. Clin. Pharmacol. 2013, 75, 645–662. [CrossRef] [PubMed]
129. O'Brien, S.M.; Scott, L.V.; Dinan, T.G. Cytokines: Abnormalities in major depression and implications for pharmacological treatment. Hum. Psychopharm. Clin. 2004, 19, 397–403. [CrossRef] [PubMed]
130. Awada, M.; Meynier, A.; Soulage, C.O.; Hadji, L.; Geloen, A.; Viau, M.; Ribourg, L.; Benoit, B.; Debard, C.; Guichardant, M.; et al. N-3 pufa added to high-fat diets affect differently adiposity and inflammation when carried by phospholipids or triacylglycerols in mice. Nutr. Metab. 2013, 10, 23–36. [CrossRef] [PubMed]
131. Lee, S.; Gura, K.M.; Kim, S.; Arsenault, D.A.; Bistrian, B.R.; Puder, M. Current clinical applications of ω-6 and ω-3 fatty acids. Nutr. Clin. Pract. 2006, 21, 323–341. [CrossRef] [PubMed]
132. Peet, M.; Horrobin, D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002, 36, 7–18. [CrossRef]
133. Appleton, K.M.; Rogers, P.J.; Ness, A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 2010, 91, 757–770. [CrossRef] [PubMed]
134. Lin, P.-Y.; Su, K.-P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 2007, 68, 1056–1061. [CrossRef]
135. Sublette, M.E.; Ellis, S.P.; Geant, A.L.; Mann, J.J. Meta-analysis of the effects of eicosapentaenoic acid (epa) in clinical trials in depression. J. Clin. Psychiatry 2011, 72, 1577–1584. [CrossRef] [PubMed]
136. Bloch, M.H.; Hannestad, J. Omega-3 fatty acids for the treatment of depression: Systematic review and meta-analysis. Mol. Psychiatry 2012, 17, 1272–1282. [CrossRef] [PubMed]
137. Hamazaki, T.; Sawazaki, S.; Itomura, M.; Asaoka, E.; Nagao, Y.; Nishimura, N.; Yazawa, K.; Kuwamori, T.; Kobayashi, M. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J. Clin. Investig. 1996, 97, 1129–1133. [CrossRef] [PubMed]
138. Hamazaki, T.; Sawazaki, S.; Nagasawa, T.; Nagao, Y.; Kanagawa, Y.; Yazawa, K. Administration of docosahexaenoic acid influences behavior and plasma catecholamine levels at times of psychological stress. Lipids 1999, 34, S33–S37. [CrossRef] [PubMed]
139. Itomura, M.; Hamazaki, K.; Sawazaki, S.; Kobayashi, M.; Terasawa, K.; Watanabe, S.; Hamazaki, T. The effect of fish oil on physical aggression in schoolchildren-a randomized, double-blind, placebo-controlled trial. J. Nutr. Biochem. 2005, 16, 163–171. [CrossRef] [PubMed]
140. Carrie, I.; Clement, M.; De Javel, D.; Frances, H.; Bourre, J.M. Phospholipid supplementation reverses behavioral and biochemical alterations induced by n-3 polyunsaturated fatty acid deficiency in mice. J. Lipid Res. 2000, 41, 473–480. [PubMed]
141. Lim, S.Y.; Suzuki, H. Dose–response effect of docosahexaenoic acid ethyl ester on maze behavior and brain fatty acid composition in adult mice. Int. J. Vitam. Nutr. Res. 2002, 72, 77–84. [CrossRef] [PubMed]
142. Moriguchi, T.; Salem, N., Jr. Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J. Neurochem. 2003, 87, 297–309. [CrossRef] [PubMed]
143. Fujino, T.; Yamamoto, T. Cloning and functional expression of a novel long-chain acyl-coa synthetase expressed in brain. J. Biochem. 1992, 111, 197–203. [PubMed]
144. Setnik, B.; Nobrega, J.N. Long-chain acyl-coenzymea synthetase-2 mrna: Increased cerebral cortex expression in an animal model of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 577–582. [CrossRef] [PubMed]
145. Vinod, K.Y.; Xie, S.; Psychoyos, D.; Hungund, B.L.; Cooper, T.B.; Tejani-Butt, S.M. Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in wistar kyoto rats. PLoS ONE 2012, 7, e36743. [CrossRef] [PubMed]
146. Peng, Y.-F.; Xiang, Y.; Wei, Y.-S. The significance of routine biochemical markers in patients with major depressive disorder. Sci. Rep. 2016, 6. [CrossRef] [PubMed]
147. Friedman, J.M.; Halaas, J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395, 763–770. [CrossRef] [PubMed]
148. Zhang, L.; Bijker, M.S.; Herzog, H. The neuropeptide y system: Pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 2011, 131, 91–113. [CrossRef] [PubMed]
149. Yang, J.L.; Liu, D.X.; Jiang, H.; Pan, F.; Ho, C.S.; Ho, R.C. The effects of high-fat-diet combined with chronic unpredictable mild stress on depression-like behavior and leptin/leprb in male rats. Sci. Rep. 2016, 6. [CrossRef] [PubMed]
150. Morales-Medina, J.C.; Dumont, Y.; Quirion, R. A possible role of neuropeptide y in depression and stress. Brain Res. 2010, 1314, 194–205. [CrossRef] [PubMed]
151. Schulz, C.; Paulus, K.; Johren, O.; Lehnert, H. Intranasal leptin reduces appetite and induces weight loss in rats with diet-induced obesity (dio). Endocrinology 2012, 153, 143–153. [CrossRef] [PubMed]
152. Simopoulos, A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21, 495–505. [CrossRef] [PubMed]
153. Leonard, B.E. The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25, 767–780. [CrossRef]
154. Parker, G.; Roy, K.; Mitchell, P. Assessing the comparative effectiveness of antidepressant therapies: A prospective clinical practice study. J. Clin. Psychiatry. 2001, 62, 117–125. [CrossRef]